JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kemerink, G. J.
Right arrow Articles by Verbeke, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kemerink, G. J.
Right arrow Articles by Verbeke, K.

Safety, Biodistribution, and Dosimetry of 99mTc-HYNIC-Annexin V, a Novel Human Recombinant Annexin V for Human Application

Gerrit J. Kemerink, PhD1, Xuan Liu, PhD2, Davy Kieffer3, Sarah Ceyssens2, Luc Mortelmans, MD, PhD2, Alfons M. Verbruggen, PhD3, Neil D. Steinmetz, MD, PhD4, Jean-Luc Vanderheyden, PhD4, Allan M. Green, MD, PhD4 and Kristin Verbeke, PhD3

1 Department of Nuclear Medicine, University Hospital Maastricht, Maastricht, The Netherlands
2 Department of Nuclear Medicine, University Hospital Gasthuisberg, Leuven, Belgium
3 Laboratory of Radiopharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, University of Leuven, Leuven, Belgium
4 Theseus Imaging Corporation, Boston, Massachusetts



View larger version (128K):

[in a new window]
  		FIGURE 1. Conjugate views from whole-body scans of 22-y-old male volunteer. Scans were acquired at about 30 min (A) and 24 h (B) after intravenous injection of 263 MBq of 99mTc-HYNIC-AnxV. In each pair, anterior view is on left and posterior view is on right.

 


View larger version (21K):

[in a new window]
  		FIGURE 2. Decay-corrected 99mTc uptake vs. time curves for liver (A), left kidney (B), spleen (C), and total body (D) after intravenous injection of 99mTc-HYNIC-AnxV. Curves representing mean (thick line) and mean ± 1 SD (thin lines) are shown. For comparison, curves representing average uptake for 99mTc-i-AnxV (dotted line) and 99mTc-BTAP-AnxV (dashed line) from previous studies are also shown (9,10).

 


View larger version (13K):

[in a new window]
  		FIGURE 3. Cumulative excreted activity in urine (decay corrected). Curves representing mean (thick line) and mean ± 1 SD (thin lines) are shown.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2003 by the Society of Nuclear Medicine.